Bita Fakhri, MD, MPH
The field of newly diagnosed multiple myeloma has evolved to demonstrate that triplet regimens are better than doublets; however, more data are required before quadruplets become the standard of care, according to Bita Fakhri, MD, MPH.
State of the Science Summit™ on Hematologic Malignancies, Fakhri shared her insight on the treatment of patients with newly diagnosed multiple myeloma.
OncLive: Please provide an overview of your presentation.
My presentation focused on frontline treatment options for patients with newly diagnosed multiple myeloma. I tried to provide an overview on what has been used historically in multiple myeloma, and how the field has evolved over the last few years. Doublet regimens have become triplet regimens. VRd, which is a combination of lenalidomide, bortezomib, and dexamethasone, is a very common regimen in the United States.
... to read the full story